Genzyme President & CEO, David Meeker, M.D., will describe how Genzyme has leveraged licensing activities and strategic collaborations to expand its commercialized products and services, to supplement its product pipeline, and to access complementary research, technology and development capabilities. An undisputed leader in lysosomal storage disorders and rare diseases broadly, Genzyme has also expanded the diversity of its product and pipeline portfolio as it has searched for novel therapeutics with the potential to meet unmet or underserved medical needs. Partnering has been a core component of Genzyme's scientific and commercial activities, evidenced by partnerships with the Mt. Sinai School of Medicine for Fabry disease treatment, BioMarin Pharmaceutical Inc. for the lysosomal storage disorder MPS I (Mucopolysaccharidosis I), Cambridge Antibody Technology for antibody therapies, and Kirin Brewing Co., Ltd. for antibody development. Dr. Meeker will describe the Genzyme approach and criteria employed when evaluating potential partnerships, and will tackle the question of how Genzyme has used licensing to help solve the innovation gap.
May 16, 2012
Licensing Executives Society (USA & Canada)
CLE (California): 1.00
CLE (Illinois): 1.00
Certified Licensing Professionals, Inc.: 1.00
LES Member Price:$0.00